Helixmith shows long-term safety and efficacy of VM202 for painful DPN patients in DPN phase 3-1b extension study

SEOUL, South Korea, Oct. 7, 2019 /PRNewswire/ -- Helixmith announces results showing VM202 met the primary and secondary endpoints – safety and efficacy at 12 months, respectively – in a phase 3 extension study (DPN 3-1b) conducted in the US for painful diabetic peripheral neuropathy...

from PR Newswire: https://ift.tt/35eOIP4